32 results on '"Giudice, Elena"'
Search Results
2. The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial
3. Maintenance therapy for newly and recurrent epithelial ovarian cancer: current therapies and future perspectives
4. 579-D Multiplex imaging of ovarian carcinoma reveals spatial cell interaction patterns predictive of immunotherapy responses
5. Advances in the Management of Recurrent Cervical Cancer: State of the Art and Future Perspectives
6. Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data
7. #765 Efficacy of maintenance with PARPi in advanced ovarian cancer according to the type of BRCA mutation
8. #881 The NUVOLA TRIAL: neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel. A phase II open-label multi-centre study
9. Abstract 1562: Correlative biomarker analysis of the phase II study of prexasertib, a cell cycle checkpoint kinase 1 (CHK1) inhibitor, in BRCA wild-type (BRCAwt), platinum-resistant recurrent, high-grade serous ovarian cancer (PR-HGSOC)
10. Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial
11. Survival outcomes in patients withBRCAmutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors
12. Genome tumor profiling in endometrial cancer and clinical relevance in endometrial cancer management: a retrospective single-center experience
13. PARP inhibitors, use early in the first-line maintenance therapy setting but with caution
14. Advanced and recurrent endometrial cancer: State of the art and future perspectives
15. TP034/#1534 Randomized phase III trial on niraparib-TSR-042 (Dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, primary peritoneal cancer platinum resistant patients: nitche trial(MITO 33)
16. TP042/#1526 A single arm phase II study on pembrolizumab in pre-neoplastic high grade HPV-related vulvar and cervical lesions
17. 2022-RA-1540-ESGO MITO 25.1: a randomized, molecular driven phase II trial of carboplatin-paclitaxel-bevacizumab vs carboplatin-paclitaxel-bevacizumab-rucaparib vs carboplatin-paclitaxel-rucaparib, selected according to HRD status, in patients with advanced (Stage III B-C-IV) ovarian, primary peritoneal and fallopian tube cancer
18. 2022-LBA-746-ESGO Implementation of a comprehensive cancer genome profiling programme into clinical practice: an italian experience in a referral centre for gynecological cancers
19. 2022-RA-1638-ESGO Randomized phase III trial on Niraparib-TSR-042 (dostarlimab) versus physician’s choice in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)
20. Does Multidomain Intervention Reduce The Risk Of Developing Dementia In MCI Patients?
21. Recent progress in the use of pharmacotherapy for endometrial cancer
22. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Management of Advanced Ovarian Cancer. A Literature Review
23. PARP Inhibitors Resistance: Mechanisms and Perspectives
24. Management of stage III and IVa uterine cancer
25. Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives
26. Gut microbiota and its influence on ovarian cancer carcinogenesis, anticancer therapy and surgical treatment: A literature review
27. Evolution of Clinical Trials in Ovarian Cancer Management over the Past 20 Years: Never Settle Down, Always Go Beyond
28. Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)
29. Refining Adjuvant Therapy for Endometrial Cancer: New Standards and Perspectives
30. Secondary cytoreduction for relapsed ovarian cancer
31. Pembrolizumab for advanced cervical cancer: safety and efficacy
32. Emerging Parenting Coordination Practices Around the Globe: What We Have Learned
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.